Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733359 | 1.00 | PDE10A (0.34) | PDE10ABRD4BRD2BRD3L3MBTL1 | |
| SCHEMBL2307114 | 0.85 | BRD4 (0.42) | BRD4BRD2BRD3L3MBTL1HRH3 | |
| SCHEMBL731968 | 0.82 | LMNA (0.42) | SMN1; SMN2HTT | |
| SCHEMBL733746 | 0.82 | SMO (0.33) | PDE10AHRH3MAPT | |
| SCHEMBL3262449 | 0.79 | HRH3 (0.35) | PDE10ABRD4BRD2BRD3L3MBTL1 | |
| SCHEMBL733502 | 0.79 | HRH3 (0.35) | PDE10ABRD4BRD2BRD3L3MBTL1 | |
| SCHEMBL1920545 | 0.73 | HRH3 (0.35) | PDE10AL3MBTL1HRH3 | |
| SCHEMBL14700307 | 0.73 | HRH3 (0.35) | PDE10AL3MBTL1HRH3 | |
| SCHEMBL733358 | 0.73 | HRH3 (0.35) | PDE10AL3MBTL1HRH3 | |
| SCHEMBL734283 | 0.71 | SCD5 (0.41) | BRD4L3MBTL1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | MC4R, CHRM4, GPR4 | PDE10A 827/4885BRD4 92/4885BRD2 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.